GW Pharmaceuticals PLC- (NASDAQ:GWPH) Shares Sold by Janney Montgomery Scott LLC

Share on StockTwits

Janney Montgomery Scott LLC reduced its position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 12.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,014 shares of the biopharmaceutical company’s stock after selling 1,319 shares during the period. Janney Montgomery Scott LLC’s holdings in GW Pharmaceuticals PLC- were worth $1,037,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Kavar Capital Partners LLC acquired a new position in GW Pharmaceuticals PLC- during the second quarter worth about $26,000. Signaturefd LLC grew its holdings in GW Pharmaceuticals PLC- by 192.5% during the third quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 154 shares during the period. Prestige Wealth Management Group LLC acquired a new position in GW Pharmaceuticals PLC- during the second quarter worth about $28,000. Pathstone Family Office LLC acquired a new position in GW Pharmaceuticals PLC- during the second quarter worth about $29,000. Finally, Valeo Financial Advisors LLC increased its stake in GW Pharmaceuticals PLC- by 322.6% in the 3rd quarter. Valeo Financial Advisors LLC now owns 262 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares in the last quarter. 82.89% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Douglas B. Snyder sold 3,756 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $13.88, for a total value of $52,133.28. Following the completion of the sale, the insider now directly owns 79,164 shares in the company, valued at approximately $1,098,796.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Douglas B. Snyder sold 5,424 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $13.04, for a total value of $70,728.96. Following the completion of the sale, the insider now owns 73,740 shares of the company’s stock, valued at $961,569.60. The disclosure for this sale can be found here. 3.60% of the stock is currently owned by insiders.

Shares of GWPH opened at $109.41 on Friday. The business’s 50-day moving average price is $122.70 and its 200 day moving average price is $154.23. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The company has a current ratio of 8.31, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $4.16 billion, a P/E ratio of -10.36 and a beta of 2.28.

GWPH has been the topic of a number of analyst reports. BidaskClub cut GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Saturday. Cowen reissued a “buy” rating and issued a $200.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Friday, July 26th. ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Wednesday, September 4th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $122.00 price target on the stock in a research note on Saturday. Finally, Bank of America reissued a “buy” rating and issued a $218.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, September 25th. One analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have assigned a buy rating to the company. GW Pharmaceuticals PLC- presently has a consensus rating of “Buy” and an average target price of $198.00.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: The role of implied volatility with call option volume

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.